Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Verge Genomics to Incorporate Emerald Digital Health Technology into its ALS Phase 1b Proof-of-Concept Clinical T****

Emerald AI platform and “invisible” sensors to capture critical patient data and measure changes in clinical function in patients treated with VRG50635

Verge Genomics, a clinical-stage, tech-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery and development, announced that Emerald Innovations’ wireless digital health technology will be used to capture critical patient data in its planned Phase 1b proof-of-concept study of the PIKfyve inhibitor VRG50635, a novel therapeutic in clinical development for amyotrophic lateral sclerosis (ALS).

AiThority Interview Insights: AiThority Interview with Dorian Selz, Co-Founder & CEO at Squirro

“Analysis of this rich and objective data will yield insights to inform and optimize future phases. We believe such a data-driven approach is crucial for clinical trials in neuroscience, where objective biomarkers are very limited and most endpoints are subjective and noisy”

Through the collaboration, Emerald’s wireless digital health sensors will be placed in study participants’ homes to continuously measure key neurological functions affected by ALS, including sleeping, breathing, walking, and mobility. Analyses of the Emerald data will be used to assess changes in patients being treated with increasing doses of VRG50635.

“We are thrilled to be the first company to integrate Emerald Innovations’ technology into an ALS study. Given the high unmet need for effective treatments and the complexity of ALS, it is imperative that we leverage innovative technology tools that make it possible to collect dense amounts of unbiased, objective patient function data to properly assess the efficacy and dose-response to VRG50635 early in clinical development,” said Diego Cadavid, MD, Verge’s Chief Medical Officer.

Read More about AiThority InterviewAiThority Interview with James Rubin, Product Manager at Google

“The partnership between Verge and Emerald stems from a shared commitment to establish a data-driven approach to clinical trials. This t**** is designed from the outset to continuously and objectively track patients’ function and their potential change in response to treatment, without requiring them to wear sensors or alter their behavior,” said Dr. Dina Katabi, the President and co-founder of Emerald Innovations. “Analysis of this rich and objective data will yield insights to inform and optimize future phases. We believe such a data-driven approach is crucial for clinical trials in neuroscience, where objective biomarkers are very limited and most endpoints are subjective and noisy,” Dr. Katabi added.

The Emerald biosensor belongs to a new class of “invisible” sensors that operate in the background, and extract health metrics by analyzing the surrounding radio signals using AI, without requiring patients to use wearable devices or to manually record their experience. One of the greatest potential benefits of the Emerald digital health sensor is the ability to enhance traditional ALS clinical t**** data by collecting objective patient data continuously or at regular intervals outside of office visits during a patient’s real-world activities to provide extensive, objective data for assessment of efficacy in clinical trials. Monitoring and data collection in ALS disease clinical trials traditionally involves subjective patient or physician reporting that includes diaries and questionnaires coupled with periodic neurological and mobility assessments in a clinical setting. These procedures provide useful information while having limitations in their precision and ability to capture data continuously rather than at brief moments in time.

 Latest AiThority Interview Insights : AiThority Interview with Sumeet Arora, Chief Development Officer at ThoughtSpot

 [To share your insights with us, please write to sghosh@martechseries.com] 

Comments are closed.